Paroxetine
Paroxetine is an SSRI (selective serotonin reuptake inhibitor) used in adults for depression and several anxiety-related conditions, and in a low-dose capsule for hot flashes from menopause.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 100 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Paroxetine is an SSRI (it keeps more serotonin active in the brain) used in adults for depression and several anxiety conditions, and as a low-dose capsule for menopausal hot flashes; on the market since about 1992 and available generically, it is a familiar older SSRI, though usually not the first one chosen. Most people tolerate it, though drowsiness, nausea, sweating and sexual side effects are common complaints. Its boxed warning covers suicidal thoughts in children, teens and young adults up to 24, so watch mood closely early on. Never stop it suddenly, since withdrawal tends to hit harder than with most SSRIs, and talk to your prescriber before stopping or planning a pregnancy.
Clinical pearls
- If you take tamoxifen for breast cancer, make sure every prescriber knows, because paroxetine may make tamoxifen less effective.
- Never combine it with MAOIs, including the antibiotic linezolid and IV methylene blue, so tell hospital teams you take it.
- Ibuprofen, naproxen, aspirin and blood thinners like warfarin raise bleeding risk with paroxetine, so report unusual bruising or bleeding.
- The low-dose menopause capsule (Brisdelle) is not for depression or anxiety, and never take two paroxetine products together.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Antidepressants, including paroxetine, can increase suicidal thoughts and behavior in children, teens, and young adults up to age 24. This was seen in short-term studies. It was not seen in adults over 24, and risk was lower in adults 65 and older.
Depression itself raises suicide risk. Anyone starting an antidepressant should be watched closely for worsening mood, suicidal thoughts, or unusual behavior changes. Families and caregivers should stay in close contact with the prescriber. Paroxetine tablets are not approved for children. Do not take any other paroxetine-containing medicine together with them.
Patient information guide A plain-language walkthrough of Paroxetine, written from its FDA label.
What Paroxetine is used for
▾
Paroxetine is used for several conditions, depending on the product.
- Paroxetine tablets and oral suspension (including Paxil): major depressive disorder, OCD, panic disorder, social anxiety disorder, generalized anxiety disorder, and PTSD in adults.
- Paroxetine extended-release tablets (including Paxil CR): major depressive disorder, panic disorder, social anxiety disorder, and PMDD in adults.
- Brisdelle and paroxetine capsules: moderate to severe menopausal hot flashes (vasomotor symptoms) only, not any psychiatric condition.
How Paroxetine works
▾
Paroxetine is an SSRI. It blocks the reuptake of serotonin by nerve cells in the central nervous system, which boosts serotonin activity. This is thought to be linked to its benefit, although the exact mechanism is unknown.
Paroxetine dosage
▾
Paroxetine is taken by mouth. Tablets and oral suspension are taken once daily, usually in the morning, with or without food. Shake the suspension well first.
- Extended-release tablets: swallow whole, once daily in the morning.
- Brisdelle and paroxetine capsules: once daily at bedtime, with or without food.
- When stopping, the dose should be lowered gradually.
Follow your prescriber and label for your dose.
Dosing details from the FDA-approved label
From the Paroxetine prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- MDD (paroxetine extended-release tablets)
- Starting dose 25 mg/day
- If inadequate response, increase in increments of 12.5 mg per day at intervals of at least 1 week
- Maximum: 62.5 mg/day
- Single daily dose in the morning, with or without food; swallow whole
- PD (paroxetine extended-release tablets)
- Starting dose 12.5 mg/day
- May increase in increments of 12.5 mg per day at intervals of at least 1 week
- Maximum: 75 mg/day
- Single daily dose in the morning, with or without food; swallow whole
- SAD (paroxetine extended-release tablets)
- Starting dose 12.5 mg/day
- May increase in increments of 12.5 mg per day at intervals of at least 1 week
- Maximum: 37.5 mg/day
- Single daily dose in the morning, with or without food; swallow whole
- PMDD (paroxetine extended-release tablets)
- Starting dose 12.5 mg per day, given continuously or intermittently (only during the luteal phase, starting 14 days prior to the anticipated onset of menstruation and continuing through the onset of menses)
- Adjust at intervals of at least 1 week
- Maximum: 25 mg per day
- Elderly, severe renal impairment, or severe hepatic impairment (extended-release tablets)
- Initial dose 12.5 mg per day
- Reduce initial dose and increase up-titration intervals if necessary
- Maximum: 50 mg per day for MDD or PD; 37.5 mg per day for SAD
- MDD (paroxetine oral suspension)
- Starting dose 20 mg
- If inadequate response, increase in increments of 10 mg per day at intervals of at least 1 week
- Maximum: 50 mg
- Single daily dose in the morning, with or without food; shake well
- OCD (paroxetine oral suspension)
- Starting dose 20 mg
- Increase in increments of 10 mg per day at intervals of at least 1 week
- Maximum: 60 mg
- PD (paroxetine oral suspension)
- Starting dose 10 mg
- Increase in increments of 10 mg per day at intervals of at least 1 week
- Maximum: 60 mg
- PTSD (paroxetine oral suspension)
- Starting dose 20 mg
- Increase in increments of 10 mg per day at intervals of at least 1 week
- Maximum: 50 mg
- SAD and GAD (paroxetine oral suspension)
- Starting and recommended dosage 20 mg daily
- If inadequate response, increase in increments of 10 mg per day at intervals of at least 1 week
- Elderly, severe renal or severe hepatic impairment: initial 10 mg per day, not to exceed 40 mg/day
Read the label’s full dosing text
DOSAGE AND ADMINISTRATION Major Depressive Disorder: Usual Initial Dosage: Paroxetine Tablets should be administered as a single daily dose with or without food, usually in the morning. The recommended initial dose is 20 mg/day. Patients were dosed in a range of 20 mg/day to 50 mg/day in the clinical trials demonstrating the effectiveness of Paroxetine Tablets in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 20-mg dose may benefit from dose increases, in 10-mg/day increments, up to a maximum of 50 mg/day. Dose changes should occur at intervals of at least 1 week. Maintenance Therapy: There is no body of evidence available to answer the question of how long the patient treated with Paroxetine Tablets should remain on it. It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy. Whether the dose needed to induce remission is identical to the dose needed to maintain and/or sustain euthymia is unknown. Systematic evaluation of the efficacy of Paroxetine Tablets has shown that efficacy is maintained for periods of up to 1 year with doses that averaged about 30 mg. Obsessive Compulsive Disorder: Usual Initial Dosage: Paroxetine Tablets should be administered as a single daily dose with or without food, usually in the morning. The recommended dose of Paroxetine Tablets in the treatment of OCD is 40 mg daily. Patients should be started on 20 mg/day and the dose can be increased in 10-mg/day increments. Dose changes should occur at intervals of at least 1 week. Patients were dosed in a range of 20 mg/day to 60 mg/day in the clinical trials demonstrating the effectiveness of Paroxetine Tablets in the treatment of OCD. The maximum dosage should not exceed 60 mg/day. Maintenance Therapy: Long-term maintenance of efficacy was demonstrated in a 6-month relapse prevention trial. In this trial, patients with OCD assigned to paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY: Clinical Trials ). OCD is a chronic condition, and it is reasonable to consider continuation for a responding patient.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Paroxetine side effects
▾
Common side effects seen in studies include:
Common side effects
- Nausea
- Sleepiness or drowsiness
- Dry mouth
- Sweating
- Constipation or diarrhea
- Dizziness
- Trouble sleeping
- Decreased appetite, weakness, or tremor
- Sexual side effects
When to get medical help
- Call your doctor right away if you have new or worsening depression, suicidal thoughts, agitation, or unusual changes in behavior.
- Seek help for possible serotonin syndrome: this can happen with other serotonin-affecting drugs, but also when paroxetine is taken alone.
- Report unusual bleeding or bruising, especially if you take aspirin, NSAIDs, or blood thinners.
- Tell your doctor if you have a seizure or symptoms of mania or hypomania (unusually high energy or elevated mood).
- Get urgent care for eye pain or vision changes, as angle-closure glaucoma has occurred.
- Tell your doctor about severe symptoms after stopping, which the label calls discontinuation syndrome.
Paroxetine warnings and precautions
▾
- Suicidal thoughts and behavior (boxed warning) in people 24 and younger.
- Serotonin syndrome, alone or with other serotonin-affecting drugs.
- Higher bleeding risk, especially with aspirin, NSAIDs, or blood thinners.
- Mania or hypomania; screen for bipolar disorder.
- Seizures, angle-closure glaucoma, low sodium, bone fracture, and sexual dysfunction.
- Fetal and newborn harm with use in pregnancy.
Paroxetine interactions
▾
Paroxetine can clash with several medicines.
- MAOIs (including linezolid and IV methylene blue): contraindicated due to serotonin syndrome.
- Thioridazine and pimozide: contraindicated due to heart rhythm risk.
- Triptans, lithium, fentanyl, tramadol, amphetamines, St. John's Wort, other SSRIs/SNRIs: raise serotonin syndrome risk.
- Tryptophan: not recommended.
- Aspirin, NSAIDs, warfarin: may raise bleeding risk.
- Tamoxifen: may be less effective.
- Tricyclic antidepressants, risperidone, atomoxetine: paroxetine can raise their levels.
Interactions listed in the FDA-approved label
From the Paroxetine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Tryptophan: Adverse experiences, primarily headache, nausea, sweating, and dizziness, have been reported when tryptophan was given to patients taking paroxetine. Concomitant use is not recommended.
- Monoamine oxidase inhibitors (including linezolid and intravenous methylene blue): Risk of serotonin syndrome. Concomitant use is contraindicated.
- Pimozide: Pimozide AUC increased 151% and Cmax 62% due to paroxetine's CYP2D6 inhibition; pimozide has a narrow therapeutic index and can prolong the QT interval. Concomitant use is contraindicated.
- Serotonergic drugs (triptans, lithium, fentanyl, tramadol, amphetamines, St. John's Wort): Potential for serotonin syndrome. Caution is advised; use with other SSRIs, SNRIs or tryptophan is not recommended.
- Thioridazine: Risk of serious ventricular arrhythmias and sudden death with elevated thioridazine plasma levels. Should not be coadministered.
- Warfarin: Possible pharmacodynamic interaction causing increased bleeding diathesis with unaltered prothrombin time. Undertake concomitant administration with caution.
- Cimetidine: Steady-state paroxetine plasma concentrations increased by approximately 50%. Dosage adjustment of paroxetine after the 20 mg starting dose should be guided by clinical effect.
- Phenobarbital: Paroxetine AUC and T1/2 reduced by an average of 25% and 38%. No initial dosage adjustment necessary; subsequent adjustment guided by clinical effect.
- Phenytoin: Paroxetine AUC and T1/2 reduced by an average of 50% and 35%; phenytoin AUC slightly reduced (12% on average). No initial dosage adjustments necessary; subsequent adjustments guided by clinical effect.
- Drugs metabolized by CYP2D6 (e.g., desipramine, risperidone, atomoxetine, tamoxifen): Paroxetine may significantly inhibit CYP2D6; desipramine Cmax, AUC and T1/2 increased about 2-, 5-, and 3-fold, risperidone about 4-fold, atomoxetine AUC 6- to 8-fold; tamoxifen efficacy may be reduced. Approach with caution; lower doses may be needed; start atomoxetine at a reduced dose.
Read the label’s full interactions text
Drug Interactions Tryptophan As with other serotonin reuptake inhibitors, an interaction between paroxetine and tryptophan may occur when they are coadministered. Adverse experiences, consisting primarily of headache, nausea, sweating, and dizziness, have been reported when tryptophan was administered to patients taking paroxetine tablets. Consequently, concomitant use of paroxetine tablets with tryptophan is not recommended (see WARNINGS: Serotonin Syndrome ). Monoamine Oxidase Inhibitors See CONTRAINDICATIONS and WARNINGS . Pimozide In a controlled study of healthy volunteers, after paroxetine tablets were titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and C max of 62%, compared to pimozide administered alone. The increase in pimozide AUC and C max is due to the CYP2D6 inhibitory properties of paroxetine. Due to the narrow therapeutic index of pimozide and its known ability to prolong the QT interval, concomitant use of pimozide and paroxetine tablets are contraindicated (see CONTRAINDICATIONS ). Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine tablets are coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, amphetamines, or St. John's Wort (see WARNINGS: Serotonin Syndrome ). The concomitant use of paroxetine tablets with MAOIs (including linezolid and intravenous methylene blue) is contraindicated (see CONTRAINDICATIONS ). The concomitant use of paroxetine tablets with other SSRIs, SNRIs or tryptophan is not recommended (see PRECAUTIONS: Drug Interactions: Tryptophan ). Thioridazine See CONTRAINDICATIONS and WARNINGS .
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Taking a supplement with Paroxetine? Snap its label. Photograph the Supplement Facts panel: we read every active ingredient and check each one against Paroxetine in the licensed interaction database. Scan a labelBefore taking Paroxetine
▾
- Do not take with MAOIs, thioridazine, or pimozide, or if allergic to paroxetine.
- Tell your doctor if pregnant, planning pregnancy, or breastfeeding. Paroxetine is secreted in breast milk.
- Paroxetine tablets are not approved for children.
- Older adults may need a lower starting dose and are at higher risk of low sodium.
- Severe kidney or liver impairment may call for a lower starting dose.
- Tell your doctor about bipolar disorder, seizures, or narrow-angle glaucoma.
Paroxetine overdose
▾
Overdose can cause sleepiness, coma, nausea, tremor, fast heartbeat, confusion, vomiting, and dizziness. Serious effects such as seizures, heart rhythm problems, and serotonin syndrome have also been reported. There is no specific antidote, so treatment is supportive. Contact a poison control center or seek emergency care.
What Paroxetine does in the body
▾
Paroxetine is a potent and highly selective blocker of serotonin reuptake, with very weak effects on norepinephrine and dopamine. It also blocks serotonin uptake into platelets. It has little affinity for several other receptors tied to sedation and cholinergic effects (anticholinergic effects) in other psychiatric drugs.
How your body processes Paroxetine
▾
Paroxetine is completely absorbed after oral dosing. Its half-life is about 21 hours, and steady levels build up over roughly 10 to 12 days. It is heavily metabolized, partly by the liver enzyme CYP2D6, into inactive metabolites. Those are mostly cleared in urine, with some in stool. Levels rise in people with kidney or liver impairment and in older adults.
How to store Paroxetine
▾
Store at 20° to 25°C (68° to 77°F). Dispense in a tight container as defined in the USP using a child-resistant closure.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Paroxetine
134 supplements and herbal products have documented interactions with Paroxetine in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 3
- Moderate · 105
- Minor · 26
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Paroxetine has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Paroxetine: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Paroxetine — the kind of thing our pharmacy team would talk through with you at the counter.
What is paroxetine used for?
▾
How should I take it?
▾
What side effects should I expect?
▾
Is there anything I should avoid taking with it?
▾
Is it safe in pregnancy?
▾
Why am I being watched closely when I start it?
▾
Is Paroxetine available over the counter?
▾
When was Paroxetine first available?
▾
Who makes Paroxetine?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Paroxetine on HelloPharmacist
Paroxetine forms and strengths (how it comes)
Paroxetine is available in 4 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Paroxetine inactive ingredients by manufacturer.
Tablet
How this form is used
- Paxil tablets are used in adults for major depressive disorder, OCD, panic disorder, social anxiety disorder, generalized anxiety disorder, and PTSD.
- Paxil is taken as a single daily dose in the morning, with or without food.
- Paxil should be lowered gradually when stopping.
Extended-release tablet
How this form is used
- Paxil CR is used in adults for major depressive disorder, panic disorder, social anxiety disorder, and PMDD.
- Paxil CR is taken as a single daily dose in the morning, with or without food.
- Paxil CR tablets are swallowed whole, not chewed or crushed.
- Paxil CR should be lowered gradually when stopping.
Capsule
How this form is used
- Brisdelle is used for moderate to severe hot flashes and night sweats from menopause.
- Brisdelle is not for any psychiatric condition.
- Brisdelle is taken once daily at bedtime, with or without food.
- Brisdelle requires at least 14 days between stopping an MAOI and starting it, and the reverse.
Oral suspension
How this form is used
- Paroxetine oral suspension is used in adults for major depressive disorder, OCD, panic disorder, social anxiety disorder, generalized anxiety disorder, and PTSD.
- Paroxetine oral suspension is taken once daily in the morning, with or without food.
- Shake paroxetine oral suspension well before each dose.
Paroxetine inactive ingredients: allergens and excipients by product
Every Paroxetine product declares its inactive ingredients on its FDA label, and they differ from one labeler to the next. 60 of 60 current Paroxetine products have been checked. Use the switches to hide the products that list what you avoid. A product with none of these listed is not certified free of them: the label says what the manufacturer declared, and the source of a starch or a flavor is often not stated.
The full comparison, with every current product, which manufacturers do and do not list each ingredient, and the questions people ask, is on its own page: Paroxetine inactive ingredients by manufacturer.
| Product | Lists | Inactive ingredients on the label |
|---|---|---|
| Legacy Pharma USA, Inc. 7.5 mg Capsule · NDC 83107-0027-30 |
Synthetic dyes Titanium dioxide Gelatin Carmine or shellac |
10 ingredientsCALCIUM PHOSPHATE, DIBASIC, ANHYDROUS, FD&C RED NO. 3, FD&C RED NO. 40, FD&C YELLOW NO. 6, FERROSOFERRIC OXIDE, GELATIN, MAGNESIUM STEARATE, SHELLAC, SODIUM STARCH GLYCOLATE TYPE A POTATO, TITANIUM DIOXIDE |
| Padagis US LLC 7.5 mg Capsule · NDC 00574-0279-30 |
Synthetic dyes Titanium dioxide Gelatin Carmine or shellac |
9 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, FD&C RED NO. 3, FD&C RED NO. 40, FD&C YELLOW NO. 6, FERROSOFERRIC OXIDE, GELATIN, UNSPECIFIED, MAGNESIUM STEARATE, SHELLAC, TITANIUM DIOXIDE |
| Solco Healthcare LLC 7.5 mg Capsule · NDC 43547-0409-03 |
Titanium dioxide Gelatin Carmine or shellac Propylene glycol |
9 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, FERROSOFERRIC OXIDE, GELATIN, UNSPECIFIED, MAGNESIUM STEARATE, POTASSIUM HYDROXIDE, PROPYLENE GLYCOL, SHELLAC, SODIUM STARCH GLYCOLATE TYPE A POTATO, TITANIUM DIOXIDE |
| Alembic Pharmaceuticals Inc. 12.5 mg Extended-release tablet · NDC 62332-0766-30 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
15 ingredientsD&C YELLOW NO. 10 ALUMINUM LAKE, FD&C YELLOW NO. 6 ALUMINUM LAKE, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A, POLYETHYLENE GLYCOL 400, POLYETHYLENE GLYCOL 6000, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Alembic Pharmaceuticals Limited 12.5 mg Extended-release tablet · NDC 46708-0766-30 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
15 ingredientsD&C YELLOW NO. 10 ALUMINUM LAKE, FD&C YELLOW NO. 6 ALUMINUM LAKE, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A, POLYETHYLENE GLYCOL 400, POLYETHYLENE GLYCOL 6000, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Apotex Corp 12.5 mg Extended-release tablet · NDC 60505-1316-03 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
16 ingredientsD&C YELLOW NO. 10, FD&C YELLOW NO. 6, FERRIC OXIDE YELLOW, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER, POLYETHYLENE GLYCOL 10000, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Apotex Corp 12.5 mg Extended-release tablet · NDC 60505-4377-03 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
16 ingredientsD&C YELLOW NO. 10, FD&C YELLOW NO. 6, FERRIC OXIDE YELLOW, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER, POLYETHYLENE GLYCOL 10000, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Cadila Pharmaceuticals Limited 12.5 mg Extended-release tablet · NDC 71209-0094-01 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
14 ingredientsFERRIC OXIDE YELLOW, GLYCERYL DIBEHENATE, HYPROMELLOSES, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A, POLYETHYLENE GLYCOL, UNSPECIFIED, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Chartwell RX, LLC 12.5 mg Extended-release tablet · NDC 62135-0425-30 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
11 ingredientsHYPROMELLOSE 2208 (100 MPA.S), LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (4500 MPA.S), POLYETHYLENE GLYCOL, UNSPECIFIED, POLYVINYL ALCOHOL (100000 MW), POVIDONE, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Lannett Company, Inc. 12.5 mg Extended-release tablet · NDC 62175-0470-32 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
11 ingredientsHYPROMELLOSE 2208 (100 MPA.S), LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (4500 MPA.S), POLYETHYLENE GLYCOL, UNSPECIFIED, POLYVINYL ALCOHOL (100000 MW), POVIDONE, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Lupin Pharmaceuticals, Inc. 12.5 mg Extended-release tablet · NDC 68180-0647-01 |
Lactose Synthetic dyes Tartrazine (FD&C Yellow No. 5) Titanium dioxide Carmine or shellac Propylene glycol Polyethylene glycol or polysorbate |
20 ingredientsALUMINUM OXIDE, CASTOR OIL, CELLULOSE, MICROCRYSTALLINE, D&C YELLOW NO. 10, FD&C YELLOW NO. 5, FD&C YELLOW NO. 6, FERROSOFERRIC OXIDE, HYPROMELLOSES, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER, POLYETHYLENE GLYCOL, UNSPECIFIED, POVIDONE K30, PROPYLENE GLYCOL, SHELLAC, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIACETIN, TRIETHYL CITRATE |
| Modavar Pharmaceuticals LLC 12.5 mg Extended-release tablet · NDC 72241-0029-10 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
14 ingredientsFERRIC OXIDE YELLOW, GLYCERYL DIBEHENATE, HYPROMELLOSES, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A, POLYETHYLENE GLYCOL, UNSPECIFIED, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Westminster Pharmaceuticals, LLC 12.5 mg Extended-release tablet · NDC 69367-0335-30 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
17 ingredientsD&C YELLOW NO. 10 ALUMINUM LAKE, FD&C BLUE NO. 2--ALUMINUM LAKE, FD&C RED NO. 40, FD&C YELLOW NO. 6, FERRIC OXIDE YELLOW, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER, POLYETHYLENE GLYCOL, UNSPECIFIED, POLYSORBATE 80, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Alembic Pharmaceuticals Inc. 25 mg Extended-release tablet · NDC 62332-0767-30 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
14 ingredientsD&C RED NO. 30 ALUMINUM LAKE, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A, POLYETHYLENE GLYCOL 400, POLYETHYLENE GLYCOL 6000, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Alembic Pharmaceuticals Limited 25 mg Extended-release tablet · NDC 46708-0767-30 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
14 ingredientsD&C RED NO. 30 ALUMINUM LAKE, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A, POLYETHYLENE GLYCOL 400, POLYETHYLENE GLYCOL 6000, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Apotex Corp 25 mg Extended-release tablet · NDC 60505-1317-03 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
15 ingredientsD&C RED NO. 30, FERRIC OXIDE RED, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER, POLYETHYLENE GLYCOL 10000, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Apotex Corp 25 mg Extended-release tablet · NDC 60505-4378-03 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
15 ingredientsD&C RED NO. 30, FERRIC OXIDE RED, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER, POLYETHYLENE GLYCOL 10000, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Bryant Ranch Prepack 25 mg Extended-release tablet · NDC 63629-8527-01 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
13 ingredientsFD&C BLUE NO. 2, HYPROMELLOSE 2208 (100 MPA.S), LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (4500 MPA.S), PIGMENT RED 48, POLYETHYLENE GLYCOL, UNSPECIFIED, POLYVINYL ALCOHOL (100000 MW), POVIDONE, UNSPECIFIED, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Cadila Pharmaceuticals Limited 25 mg Extended-release tablet · NDC 71209-0095-01 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
14 ingredientsFERRIC OXIDE YELLOW, GLYCERYL DIBEHENATE, HYPROMELLOSES, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A, POLYETHYLENE GLYCOL, UNSPECIFIED, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Chartwell RX, LLC 25 mg Extended-release tablet · NDC 62135-0426-30 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
13 ingredientsFD&C BLUE NO. 2, HYPROMELLOSE 2208 (100 MPA.S), LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (4500 MPA.S), PIGMENT RED 48, POLYETHYLENE GLYCOL, UNSPECIFIED, POLYVINYL ALCOHOL (100000 MW), POVIDONE, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Lannett Company, Inc. 25 mg Extended-release tablet · NDC 62175-0471-32 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
13 ingredientsFD&C BLUE NO. 2, HYPROMELLOSE 2208 (100 MPA.S), LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (4500 MPA.S), PIGMENT RED 48, POLYETHYLENE GLYCOL, UNSPECIFIED, POLYVINYL ALCOHOL (100000 MW), POVIDONE, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Lupin Pharmaceuticals, Inc. 25 mg Extended-release tablet · NDC 68180-0646-01 |
Lactose Synthetic dyes Titanium dioxide Carmine or shellac Propylene glycol Polyethylene glycol or polysorbate |
19 ingredientsALUMINUM OXIDE, CASTOR OIL, CELLULOSE, MICROCRYSTALLINE, D&C RED NO. 30, FD&C BLUE NO. 2, FERROSOFERRIC OXIDE, HYPROMELLOSES, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER, POLYETHYLENE GLYCOL, UNSPECIFIED, POVIDONE K30, PROPYLENE GLYCOL, SHELLAC, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIACETIN, TRIETHYL CITRATE |
| Modavar Pharmaceuticals LLC 25 mg Extended-release tablet · NDC 72241-0030-10 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
14 ingredientsFERRIC OXIDE YELLOW, GLYCERYL DIBEHENATE, HYPROMELLOSES, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A, POLYETHYLENE GLYCOL, UNSPECIFIED, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Westminster Pharmaceuticals, LLC 25 mg Extended-release tablet · NDC 69367-0336-30 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
15 ingredientsFERRIC OXIDE RED, FERRIC OXIDE YELLOW, FERROSOFERRIC OXIDE, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER, POLYETHYLENE GLYCOL, UNSPECIFIED, POLYSORBATE 80, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Alembic Pharmaceuticals Inc. 37.5 mg Extended-release tablet · NDC 62332-0768-30 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
13 ingredientsFD&C BLUE NO. 2 ALUMINUM LAKE, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A, POLYETHYLENE GLYCOL 400, POLYETHYLENE GLYCOL 6000, POVIDONE K30, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Alembic Pharmaceuticals Limited 37.5 mg Extended-release tablet · NDC 46708-0768-30 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
13 ingredientsFD&C BLUE NO. 2 ALUMINUM LAKE, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A, POLYETHYLENE GLYCOL 400, POLYETHYLENE GLYCOL 6000, POVIDONE K30, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Apotex Corp 37.5 mg Extended-release tablet · NDC 60505-1318-03 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
15 ingredientsFD&C BLUE NO. 2, FERRIC OXIDE YELLOW, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER, POLYETHYLENE GLYCOL 10000, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Apotex Corp 37.5 mg Extended-release tablet · NDC 60505-4379-03 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
15 ingredientsFD&C BLUE NO. 2, FERRIC OXIDE YELLOW, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER, POLYETHYLENE GLYCOL 10000, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Cadila Pharmaceuticals Limited 37.5 mg Extended-release tablet · NDC 71209-0096-01 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
14 ingredientsFERRIC OXIDE YELLOW, GLYCERYL DIBEHENATE, HYPROMELLOSES, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A, POLYETHYLENE GLYCOL, UNSPECIFIED, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Chartwell RX, LLC 37.5 mg Extended-release tablet · NDC 62135-0427-30 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
12 ingredientsFD&C BLUE NO. 2, HYPROMELLOSE 2208 (100 MPA.S), LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (4500 MPA.S), POLYETHYLENE GLYCOL, UNSPECIFIED, POLYVINYL ALCOHOL (100000 MW), POVIDONE, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Lannett Company, Inc. 37.5 mg Extended-release tablet · NDC 62175-0472-32 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
12 ingredientsFD&C BLUE NO. 2, HYPROMELLOSE 2208 (100 MPA.S), LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (4500 MPA.S), POLYETHYLENE GLYCOL, UNSPECIFIED, POLYVINYL ALCOHOL (100000 MW), POVIDONE, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Lupin Pharmaceuticals, Inc. 37.5 mg Extended-release tablet · NDC 68180-0645-01 |
Lactose Synthetic dyes Titanium dioxide Carmine or shellac Propylene glycol Polyethylene glycol or polysorbate |
18 ingredientsALUMINUM OXIDE, CASTOR OIL, CELLULOSE, MICROCRYSTALLINE, FD&C BLUE NO. 1, FERROSOFERRIC OXIDE, HYPROMELLOSES, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER, POLYETHYLENE GLYCOL, UNSPECIFIED, POVIDONE K30, PROPYLENE GLYCOL, SHELLAC, SILICON DIOXIDE, TALC, TITANIUM DIOXIDE, TRIACETIN, TRIETHYL CITRATE |
| Modavar Pharmaceuticals LLC 37.5 mg Extended-release tablet · NDC 72241-0031-10 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
14 ingredientsFERRIC OXIDE YELLOW, GLYCERYL DIBEHENATE, HYPROMELLOSES, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A, POLYETHYLENE GLYCOL, UNSPECIFIED, POLYSORBATE 80, POVIDONE K30, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| Westminster Pharmaceuticals, LLC 37.5 mg Extended-release tablet · NDC 69367-0337-30 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
14 ingredientsFD&C BLUE NO. 2--ALUMINUM LAKE, FERRIC OXIDE YELLOW, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER, POLYETHYLENE GLYCOL, UNSPECIFIED, POLYSORBATE 80, SILICON DIOXIDE, SODIUM LAURYL SULFATE, TALC, TITANIUM DIOXIDE, TRIETHYL CITRATE |
| ANI Pharmaceuticals, Inc. 10 mg/5 mL Oral suspension · NDC 70954-0319-10 |
Synthetic dyes Propylene glycol Sorbitol or mannitol |
15 ingredientsANHYDROUS CITRIC ACID, CARBOXYMETHYLCELLULOSE SODIUM, CELLULOSE, MICROCRYSTALLINE, DIMETHICONE, FD&C YELLOW NO. 6, GLYCERIN, METHYLPARABEN, POLACRILIN POTASSIUM, PROPYLENE GLYCOL, PROPYLPARABEN, SACCHARIN SODIUM MONOHYDRATE, SORBITOL, TRIACETIN, TRISODIUM CITRATE DIHYDRATE, WATER |
| Camber Pharmaceuticals, Inc. 10 mg/5 mL Oral suspension · NDC 31722-0578-25 |
Synthetic dyes Propylene glycol Sorbitol or mannitol |
15 ingredientsANHYDROUS CITRIC ACID, CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED, DIMETHICONE, FD&C YELLOW NO. 6, GLYCERIN, METHYLPARABEN, MICROCRYSTALLINE CELLULOSE, NONCRYSTALLIZING SORBITOL SOLUTION, ORANGE, POLACRILIN POTASSIUM, PROPYLENE GLYCOL, PROPYLPARABEN, SACCHARIN SODIUM, TRISODIUM CITRATE DIHYDRATE, WATER |
| A-S Medication Solutions 10 mg Tablet · NDC 50090-1297-00 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
9 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, ANHYDROUS LACTOSE, HYDROXYPROPYL METHYLCELLULOSE, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 6000, POVIDONE, SODIUM STARCH GLYCOLATE TYPE A POTATO, TALC, TITANIUM DIOXIDE |
| American Health Packaging 10 mg Tablet · NDC 68084-0044-01 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
9 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, ANHYDROUS LACTOSE, HYPROMELLOSE, UNSPECIFIED, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 6000, POVIDONE, UNSPECIFIED, SODIUM STARCH GLYCOLATE TYPE A POTATO, TALC, TITANIUM DIOXIDE |
| Aphena Pharma Solutions - Tennessee, LLC 10 mg Tablet · NDC 71610-0204-60 |
Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
12 ingredientsDIBASIC CALCIUM PHOSPHATE DIHYDRATE, FD&C BLUE NO. 1, HYDROXYPROPYL CELLULOSE, UNSPECIFIED, HYPROMELLOSE, UNSPECIFIED, MAGNESIUM STEARATE, MICROCRYSTALLINE CELLULOSE, POLYDEXTROSE, POLYETHYLENE GLYCOL, UNSPECIFIED, SODIUM LAURYL SULFATE, SODIUM STARCH GLYCOLATE TYPE A POTATO, TITANIUM DIOXIDE, TRIACETIN |
| Apotex Corp 10 mg Tablet · NDC 60505-4517-03 |
Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
9 ingredientsD&C YELLOW NO. 10, DIBASIC CALCIUM PHOSPHATE DIHYDRATE, FD&C YELLOW NO. 6, HYPROMELLOSE, UNSPECIFIED, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL, UNSPECIFIED, POLYSORBATE 80, SODIUM STARCH GLYCOLATE TYPE B POTATO, TITANIUM DIOXIDE |
| Apotex Corp. 10 mg Tablet · NDC 60505-0097-01 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
7 ingredientsANHYDROUS LACTOSE, HYDROXYPROPYL CELLULOSE (1600000 WAMW), HYPROMELLOSE, UNSPECIFIED, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 8000, SODIUM STARCH GLYCOLATE TYPE A POTATO, TITANIUM DIOXIDE |
| Asclemed USA, Inc. 10 mg Tablet · NDC 76420-0716-01 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
9 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, ANHYDROUS LACTOSE, HYPROMELLOSES, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 6000, POVIDONE, SODIUM STARCH GLYCOLATE TYPE A POTATO, TALC, TITANIUM DIOXIDE |
| Aurobindo Pharma Limited 10 mg Tablet · NDC 65862-0154-01 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
11 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, D&C YELLOW NO. 10, DIBASIC CALCIUM PHOSPHATE DIHYDRATE, FD&C YELLOW NO. 6, HYPROMELLOSE 2910 (6 MPA.S), LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 6000, POLYSORBATE 80, SODIUM STARCH GLYCOLATE TYPE A POTATO, TITANIUM DIOXIDE |
| Aurolife Pharma LLC 10 mg Tablet · NDC 13107-0154-01 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
11 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, D&C YELLOW NO. 10, DIBASIC CALCIUM PHOSPHATE DIHYDRATE, FD&C YELLOW NO. 6, HYPROMELLOSE 2910 (6 MPA.S), LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 400, POLYSORBATE 80, SODIUM STARCH GLYCOLATE TYPE A POTATO, TITANIUM DIOXIDE |
| AvPAK 10 mg Tablet · NDC 50268-0640-15 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
11 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, D&C YELLOW NO. 10, DIBASIC CALCIUM PHOSPHATE DIHYDRATE, FD&C YELLOW NO. 6, HYPROMELLOSES, LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 6000, POLYSORBATE 80, SODIUM STARCH GLYCOLATE TYPE A POTATO, TITANIUM DIOXIDE |
| Bryant Ranch Prepack 10 mg Tablet · NDC 71335-0544-01 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
9 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, ANHYDROUS LACTOSE, HYPROMELLOSE, UNSPECIFIED, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 6000, POVIDONE, UNSPECIFIED, SODIUM STARCH GLYCOLATE TYPE A POTATO, TALC, TITANIUM DIOXIDE |
| Chartwell RX, LLC. 10 mg Tablet · NDC 62135-0541-90 |
Starch, source not stated Maltodextrin, source not stated Titanium dioxide |
12 ingredientsDIBASIC CALCIUM PHOSPHATE DIHYDRATE, FERRIC OXIDE RED, FERRIC OXIDE YELLOW, FERROSOFERRIC OXIDE, HYPROMELLOSE, UNSPECIFIED, MAGNESIUM STEARATE, MALTODEXTRIN, MEDIUM-CHAIN TRIGLYCERIDES, POLYDEXTROSE, SODIUM STARCH GLYCOLATE TYPE A, TALC, TITANIUM DIOXIDE |
| Direct_Rx 10 mg Tablet · NDC 72189-0492-30 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
9 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, ANHYDROUS LACTOSE, HYPROMELLOSES, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 6000, POVIDONE, SODIUM STARCH GLYCOLATE TYPE A POTATO, TALC, TITANIUM DIOXIDE |
| Golden State Medical Supply, Inc. 10 mg Tablet · NDC 60429-0734-10 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
7 ingredientsANHYDROUS LACTOSE, HYDROXYPROPYL CELLULOSE (1600000 WAMW), HYPROMELLOSE, UNSPECIFIED, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 8000, SODIUM STARCH GLYCOLATE TYPE A POTATO, TITANIUM DIOXIDE |
| Hawaii Repack, Inc. 10 mg Tablet · NDC 85534-0026-00 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
9 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, ANHYDROUS LACTOSE, HYPROMELLOSES, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 6000, POVIDONE, SODIUM STARCH GLYCOLATE TYPE A POTATO, TALC, TITANIUM DIOXIDE |
| Major Pharmaceuticals 10 mg Tablet · NDC 00904-5676-61 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
7 ingredientsANHYDROUS LACTOSE, HYDROXYPROPYL CELLULOSE (1600000 WAMW), HYPROMELLOSE, UNSPECIFIED, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 8000, SODIUM STARCH GLYCOLATE TYPE A POTATO, TITANIUM DIOXIDE |
| Mylan Pharmaceuticals Inc. 10 mg Tablet · NDC 00378-7001-10 |
Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
13 ingredientsDIBASIC CALCIUM PHOSPHATE DIHYDRATE, FD&C BLUE NO. 1, HYDROXYPROPYL CELLULOSE, UNSPECIFIED, HYPROMELLOSE, UNSPECIFIED, MAGNESIUM STEARATE, MICROCRYSTALLINE CELLULOSE 102, POLYDEXTROSE, POLYETHYLENE GLYCOL 400, POLYETHYLENE GLYCOL 8000, SODIUM LAURYL SULFATE, SODIUM STARCH GLYCOLATE TYPE A POTATO, TITANIUM DIOXIDE, TRIACETIN |
| NCS HealthCare of KY, LLC dba Vangard Labs 10 mg Tablet · NDC 00615-8359-39 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
11 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, D&C YELLOW NO. 10, DIBASIC CALCIUM PHOSPHATE DIHYDRATE, FD&C YELLOW NO. 6, HYPROMELLOSE 2910 (6 MPA.S), LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 400, POLYSORBATE 80, SODIUM STARCH GLYCOLATE TYPE A POTATO, TITANIUM DIOXIDE |
| NorthStar Rx LLC 10 mg Tablet · NDC 16714-0181-01 |
Lactose Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
11 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, D&C YELLOW NO. 10, DIBASIC CALCIUM PHOSPHATE DIHYDRATE, FD&C YELLOW NO. 6, HYPROMELLOSE 2910 (6 MPA.S), LACTOSE MONOHYDRATE, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 6000, POLYSORBATE 80, SODIUM STARCH GLYCOLATE TYPE A POTATO, TITANIUM DIOXIDE |
| NuCare Pharamceuticals, Inc. 10 mg Tablet · NDC 68071-2535-09 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
9 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, ANHYDROUS LACTOSE, HYPROMELLOSES, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 6000, POVIDONE, SODIUM STARCH GLYCOLATE TYPE A POTATO, TALC, TITANIUM DIOXIDE |
| NuCare Pharmaceuticals, Inc. 10 mg Tablet · NDC 68071-3843-01 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
8 ingredientsFERRIC OXIDE RED, FERRIC OXIDE YELLOW, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM PALMITOSTEARATE, POLYETHYLENE GLYCOL, UNSPECIFIED, TITANIUM DIOXIDE |
| NuCare Pharmaceuticals,Inc. 10 mg Tablet · NDC 68071-1740-01 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
9 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, ANHYDROUS LACTOSE, HYPROMELLOSES, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 6000, POVIDONE, SODIUM STARCH GLYCOLATE TYPE A POTATO, TALC, TITANIUM DIOXIDE |
| Oxford Pharmaceuticals, LLC 10 mg Tablet · NDC 69584-0671-03 |
Synthetic dyes Titanium dioxide Polyethylene glycol or polysorbate |
9 ingredientsDibasic Calcium Phosphate Dihydrate, Fd&C Yellow No. 6, Hypromellose, Unspecified, Magnesium Stearate, Polydextrose, Polyethylene Glycol, Unspecified, Sodium Starch Glycolate Type A Potato, Titanium Dioxide, Triacetin |
| PD-Rx Pharmaceuticals, Inc. 10 mg Tablet · NDC 72789-0379-90 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
8 ingredientsFERRIC OXIDE RED, FERRIC OXIDE YELLOW, GLYCERYL DIBEHENATE, HYPROMELLOSE, UNSPECIFIED, LACTOSE MONOHYDRATE, MAGNESIUM PALMITOSTEARATE, POLYETHYLENE GLYCOL, UNSPECIFIED, TITANIUM DIOXIDE |
| Preferred Pharmaceuticals, Inc 10 mg Tablet · NDC 68788-0797-01 |
Lactose Titanium dioxide Polyethylene glycol or polysorbate |
9 ingredientsANHYDROUS DIBASIC CALCIUM PHOSPHATE, ANHYDROUS LACTOSE, HYPROMELLOSE, UNSPECIFIED, MAGNESIUM STEARATE, POLYETHYLENE GLYCOL 6000, POVIDONE, UNSPECIFIED, SODIUM STARCH GLYCOLATE TYPE A POTATO, TALC, TITANIUM DIOXIDE |
Source: each product’s FDA-filed SPL label (DailyMed), as our label sync last read it. The concern groups are our classification of the names the label declares and never a certificate of absence; confirm with your pharmacist before relying on them.
Paroxetine on the U.S. market: products, makers and brands
How Paroxetine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
43 companies list 168 Paroxetine product records with the FDA, mostly as tablet, extended-release tablet, capsule; the earliest marketing or approval year on record is 1992. Brand names on the directory include Brisdelle, Paxil, Paxil Cr and 1 more; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (27) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Paroxetine is used (Medicaid data)
A general measure of how commonly Paroxetine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Paroxetine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Paroxetine prescribed? Of the 1,601 medications we measure, Paroxetine ranks #155 by Medicaid prescriptions — more than 90% of them.
Utilization by Paroxetine product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
paroxetine hydrochloride 20 MG Oral Tablet Most dispensed
Summed across the 25 of 190 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1738495
paroxetine hydrochloride 40 MG Oral Tablet
Summed across the 20 of 133 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1738511
paroxetine hydrochloride 10 MG Oral Tablet
Summed across the 23 of 158 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1738483
paroxetine hydrochloride 30 MG Oral Tablet
Summed across the 18 of 109 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1738503
24 HR paroxetine hydrochloride 25 MG Extended Release Oral Tablet
Summed across the 7 of 42 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1738805
24 HR paroxetine hydrochloride 37.5 MG Extended Release Oral Tablet
Summed across the 5 of 24 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1738807
24 HR paroxetine hydrochloride 12.5 MG Extended Release Oral Tablet
Summed across the 5 of 26 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1738803
paroxetine mesylate 7.5 MG Oral Capsule
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1430122
paroxetine hydrochloride 2 MG/ML Oral Suspension
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 312242
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Paroxetine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 106 of 690 listed Paroxetine NDCs with Medicaid activity.
Compare Paroxetine products
A representative set of FDA-listed product records for Paroxetine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 7.5 mg | Oral | Legacy Pharma USA, Inc. | NDA | View NDC → |
| 7.5 mg | Oral | Padagis US LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 7.5 mg | Oral | Solco Healthcare LLC | ANDA | View NDC → |
| 💊Extended-release tablet | ||||
| 12.5 mg | Oral | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 25 mg | Oral | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 37.5 mg | Oral | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 12.5 mg | Oral | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| 25 mg | Oral | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| 37.5 mg | Oral | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| 12.5 mg | Oral | Apotex Corp | NDA AUTHORIZED GENERIC | View NDC → |
| 12.5 mg | Oral | Apotex Corp | NDA | View NDC → |
| 25 mg | Oral | Apotex Corp | NDA AUTHORIZED GENERIC | View NDC → |
| 25 mg | Oral | Apotex Corp | NDA | View NDC → |
| 37.5 mg | Oral | Apotex Corp | NDA AUTHORIZED GENERIC | View NDC → |
| 37.5 mg | Oral | Apotex Corp | NDA | View NDC → |
| 25 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 12.5 mg | Oral | Cadila Pharmaceuticals Limited | ANDA | View NDC → |
| 25 mg | Oral | Cadila Pharmaceuticals Limited | ANDA | View NDC → |
| 37.5 mg | Oral | Cadila Pharmaceuticals Limited | ANDA | View NDC → |
| 12.5 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 25 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 37.5 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 12.5 mg | Oral | Lannett Company, Inc. | ANDA | View NDC → |
| 25 mg | Oral | Lannett Company, Inc. | ANDA | View NDC → |
| 37.5 mg | Oral | Lannett Company, Inc. | ANDA | View NDC → |
| 12.5 mg | Oral | Lupin Pharmaceuticals, Inc. | ANDA | View NDC → |
| 25 mg | Oral | Lupin Pharmaceuticals, Inc. | ANDA | View NDC → |
| 37.5 mg | Oral | Lupin Pharmaceuticals, Inc. | ANDA | View NDC → |
| 12.5 mg | Oral | Modavar Pharmaceuticals LLC | ANDA | View NDC → |
| 25 mg | Oral | Modavar Pharmaceuticals LLC | ANDA | View NDC → |
| 37.5 mg | Oral | Modavar Pharmaceuticals LLC | ANDA | View NDC → |
| 12.5 mg | Oral | Westminster Pharmaceuticals, LLC | ANDA | View NDC → |
| 25 mg | Oral | Westminster Pharmaceuticals, LLC | ANDA | View NDC → |
| 37.5 mg | Oral | Westminster Pharmaceuticals, LLC | ANDA | View NDC → |
| 💊Oral suspension | ||||
| 10 mg/5 mL | Oral | ANI Pharmaceuticals, Inc. | ANDA | View NDC → |
| 10 mg/5 mL | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 💊Tablet | ||||
| 10 mg | Oral | A-S Medication Solutions | ANDA | View NDC → |
| 20 mg | Oral | A-S Medication Solutions | ANDA | View NDC → |
| 30 mg | Oral | A-S Medication Solutions | ANDA | View NDC → |
| 20 mg | Oral | Advanced Rx Pharmacy of Tennessee, LLC | ANDA | View NDC → |
| 10 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 20 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 30 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 40 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 10 mg | Oral | Aphena Pharma Solutions - Tennessee, LLC | ANDA | View NDC → |
| 20 mg | Oral | Aphena Pharma Solutions - Tennessee, LLC × 3 listings | ANDA | View NDC → |
| 30 mg | Oral | Aphena Pharma Solutions - Tennessee, LLC | ANDA | View NDC → |
| 40 mg | Oral | Aphena Pharma Solutions - Tennessee, LLC × 4 listings | ANDA | View NDC → |
| 10 mg | Oral | Apotex Corp | NDA | View NDC → |
| 20 mg | Oral | Apotex Corp | NDA | View NDC → |
| 30 mg | Oral | Apotex Corp | NDA | View NDC → |
| 40 mg | Oral | Apotex Corp | NDA | View NDC → |
| 10 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 20 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 30 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 40 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 10 mg | Oral | Asclemed USA, Inc. | ANDA | View NDC → |
| 20 mg | Oral | Asclemed USA, Inc. | ANDA | View NDC → |
| 30 mg | Oral | Asclemed USA, Inc. | ANDA | View NDC → |
| 40 mg | Oral | Asclemed USA, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 20 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 30 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 40 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 10 mg | Oral | Aurolife Pharma LLC | ANDA | View NDC → |
| 20 mg | Oral | Aurolife Pharma LLC | ANDA | View NDC → |
| 30 mg | Oral | Aurolife Pharma LLC | ANDA | View NDC → |
| 40 mg | Oral | Aurolife Pharma LLC | ANDA | View NDC → |
| 10 mg | Oral | AvPAK | ANDA | View NDC → |
| 30 mg | Oral | AvPAK | ANDA | View NDC → |
| 40 mg | Oral | AvPAK | ANDA | View NDC → |
| 10 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 20 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 30 mg | Oral | Bryant Ranch Prepack × 2 listings | ANDA | View NDC → |
| 40 mg | Oral | Bryant Ranch Prepack × 2 listings | ANDA | View NDC → |
| 20 mg | Oral | Cardinal Health 107, LLC | ANDA | View NDC → |
| 10 mg | Oral | Chartwell RX, LLC. | ANDA | View NDC → |
| 20 mg | Oral | Chartwell RX, LLC. | ANDA | View NDC → |
| 30 mg | Oral | Chartwell RX, LLC. | ANDA | View NDC → |
| 40 mg | Oral | Chartwell RX, LLC. | ANDA | View NDC → |
| 30 mg | Oral | Coupler LLC | ANDA | View NDC → |
| 40 mg | Oral | Coupler LLC | ANDA | View NDC → |
| 40 mg | Oral | Direct Rx | ANDA | View NDC → |
| 10 mg | Oral | Direct_Rx | ANDA | View NDC → |
| 10 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 20 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 30 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 40 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Hawaii Repack, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Major Pharmaceuticals | ANDA | View NDC → |
| 20 mg | Oral | Major Pharmaceuticals | ANDA | View NDC → |
| 10 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| 20 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| 30 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| 40 mg | Oral | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| 10 mg | Oral | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | View NDC → |
| 20 mg | Oral | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | View NDC → |
| 30 mg | Oral | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | View NDC → |
| 40 mg | Oral | NCS HealthCare of KY, LLC dba Vangard Labs | ANDA | View NDC → |
| 10 mg | Oral | NorthStar Rx LLC | ANDA | View NDC → |
| 20 mg | Oral | NorthStar Rx LLC | ANDA | View NDC → |
| 30 mg | Oral | NorthStar Rx LLC | ANDA | View NDC → |
| 40 mg | Oral | NorthStar Rx LLC | ANDA | View NDC → |
| 10 mg | Oral | NuCare Pharamceuticals, Inc. | ANDA | View NDC → |
| 10 mg | Oral | NuCare Pharmaceuticals, Inc. × 2 listings | ANDA | View NDC → |
| 10 mg | Oral | NuCare Pharmaceuticals,Inc. | ANDA | View NDC → |
| 20 mg | Oral | NuCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Oxford Pharmaceuticals, LLC | ANDA | View NDC → |
| 20 mg | Oral | Oxford Pharmaceuticals, LLC | ANDA | View NDC → |
| 30 mg | Oral | Oxford Pharmaceuticals, LLC | ANDA | View NDC → |
| 40 mg | Oral | Oxford Pharmaceuticals, LLC | ANDA | View NDC → |
| 10 mg | Oral | PD-Rx Pharmaceuticals, Inc. × 2 listings | ANDA | View NDC → |
| 20 mg | Oral | PD-Rx Pharmaceuticals, Inc. | ANDA | View NDC → |
| 40 mg | Oral | PD-Rx Pharmaceuticals, Inc. × 2 listings | ANDA | View NDC → |
| 10 mg | Oral | Preferred Pharmaceuticals, Inc | ANDA | View NDC → |
| 20 mg | Oral | Preferred Pharmaceuticals, Inc | ANDA | View NDC → |
| 10 mg | Oral | Preferred Pharmaceuticals Inc. | ANDA | View NDC → |
| 20 mg | Oral | Preferred Pharmaceuticals Inc. × 2 listings | ANDA | View NDC → |
| 30 mg | Oral | Preferred Pharmaceuticals Inc. | ANDA | View NDC → |
| 40 mg | Oral | Preferred Pharmaceuticals Inc. | ANDA | View NDC → |
| 10 mg | Oral | Proficient Rx LP × 2 listings | ANDA | View NDC → |
| 20 mg | Oral | Proficient Rx LP × 3 listings | ANDA | View NDC → |
| 40 mg | Oral | Proficient Rx LP × 2 listings | ANDA | View NDC → |
| 10 mg | Oral | Remedyrepack Inc. × 4 listings | ANDA | View NDC → |
| 20 mg | Oral | Remedyrepack Inc. × 3 listings | ANDA | View NDC → |
| 30 mg | Oral | Remedyrepack Inc. × 4 listings | ANDA | View NDC → |
| 40 mg | Oral | Remedyrepack Inc. × 3 listings | ANDA | View NDC → |
| 10 mg | Oral | Solco Healthcare US, LLC | ANDA | View NDC → |
| 20 mg | Oral | Solco Healthcare US, LLC | ANDA | View NDC → |
| 30 mg | Oral | Solco Healthcare US, LLC | ANDA | View NDC → |
| 40 mg | Oral | Solco Healthcare US, LLC | ANDA | View NDC → |
| 10 mg | Oral | Yiling Pharmaceutical, Inc. | ANDA | View NDC → |
| 20 mg | Oral | Yiling Pharmaceutical, Inc. | ANDA | View NDC → |
| 30 mg | Oral | Yiling Pharmaceutical, Inc. | ANDA | View NDC → |
| 40 mg | Oral | Yiling Pharmaceutical, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 20 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 30 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 40 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 10 mg | Oral | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 20 mg | Oral | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 30 mg | Oral | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 40 mg | Oral | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
Showing 168 of 168 products — FDA National Drug Code Directory. See every product, package size and price: browse all 168 Paroxetine NDCs →
Paroxetine side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Paroxetine — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Paroxetine are fatigue, nausea, drug interaction; about 82% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Paroxetine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Paroxetine FDA approval history
How Paroxetine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Paroxetine was first approved by the FDA in 1992 (Brand: PAXIL · Apotex); the first generic version was approved in 2003. It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Paroxetine recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list 2 Paroxetine recalls since July 2021, covering 7 product listings. One of them is still ongoing and is listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Paroxetine Hydrochloride Tablets USP, RX only, 40 mg, 1000-count bottle, NDC#:60505-0101-4 Manufactured by: Apotex Inc., Toronto, Ontario, Canada M9L 1T9, Manufactured for: Apotex Corp., Weston, Flor… Lots: Lot numbers: RV0131, RV2387, RV2389, RW3296, RV2388; Exp. 08/2024 FDA record D-0122-2024 →
- Paroxetine Hydrochloride Tablets USP, RX only, 30 mg, a)30-count bottle, NDC#: 60505-0084-1, b)100-count bottle, NDC#:60505-0084-2, c)1000-count bottle, NDC#: 60505-0084-4, Manufactured by: Apotex In… Lots: Lot numbers: a)100 count bottle: RV8686; b) 1000 count bottle: RX0119; c) 30 count bottle: RV2254; Exp. 08/2024 FDA record D-0121-2024 →
- Paroxetine Hydrochloride Tablets USP, RX only, 20 mg, a) 100-count bottle, NDC#:60505-0083-2; b) 1000-count bottle, NDC#: 60505-0083-4 Manufactured by: Apotex Inc., Toronto, Ontario, Canada M9L 1T9,… Lots: Lot numbers: a)100 count bottle: RV2384, RV2385; b) 1000 count bottle: RV2396, RV2397; Exp. 08/2024 FDA record D-0120-2024 →
- Paroxetine Hydrochloride Tablets USP, RX only, 10 mg a) 30-count bottle, NDC#: 60505-0097-1; b) 100-count bottle, NDC#: 60505-0097-2; c) 1000-count bottle, NDC#: 60505-0097-4, Manufactured by: Apotex… Lots: Lot numbers: a)100 count bottle: RV2376, RV2377; b) 1000 count bottle: RV2379, RV2380; c) 30 count bottle: RV2375; Exp. 08/2024 FDA record D-0119-2024 →
- PAROXETINE tablets, USP, 40 mg, Packaged as a) 30-count bottle, NDC 60429-737-30; b) 90-count bottle NDC 60429-737-90; c)1000-count bottle, NDC 60429-737-10; Rx Only, Manufactured by Apotex, Inc., To… Lots: Lot # a) GS036488, GS037091, GS037701, Exp. 08/31/2024; b) GS037090, GS037702, Exp. 08/31/2024; c) GS036677, GS037117, GS037699, Exp. 08/31/2024 FDA record D-0130-2024 →
- PAROXETINE tablets, USP, 20 mg, Packaged as a) 90-count bottle NDC 60429-735-90; b)1000-count bottle, NDC 60429-735-10; Rx Only, Manufactured by Apotex, Inc., Toronto, Ontario, Canada, M9L 1T9, Packa… Lots: Lot # a) GS036696, GS037068, GS037934, GS038564, Exp. 08/31/2024 b) GS036381, GS036712, GS037116, GS037692, GS038388, Exp. 08/31/2024; FDA record D-0129-2024 →
- PAROXETINE tablets, USP, 10 mg, Packaged as a) 30-count bottle, NDC 60429-734-30; b) 90-count bottle NDC 60429-734-90; c)1000-count bottle, NDC 60429-734-10; Rx Only, Manufactured by Apotex, Inc., To… Lots: Lot # a) Lot GS041383, GS042141, Exp. 08/31/2024; b) Lot GS040841, Lot GS041384, Lot GS042039, Exp. 08/31/2024; c) Lot GS040910, Lot GS041621, Lot GS042237, Exp. 08/31/2024; FDA record D-0128-2024 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 32937 4 dose forms · 13 strengths
-
Dose form (SCDF) Extended Release Oral Tablet RxCUI 562789In current FDA listingsClinical drug / strength (SCD) 24 HR paroxetine hydrochloride 12.5 MGRxCUI 173880324 HR paroxetine hydrochloride 25 MGRxCUI 173880524 HR paroxetine hydrochloride 37.5 MGRxCUI 1738807 -
Dose form (SCDF) Oral Capsule RxCUI 1430121In current FDA listingsClinical drug / strength (SCD) mesylate 7.5 MGRxCUI 1430122 -
Dose form (SCDF) Oral Suspension RxCUI 373245In current FDA listingsClinical drug / strength (SCD) hydrochloride 2 MG/MLRxCUI 312242 -
Dose form (SCDF) Oral Tablet RxCUI 378925In current FDA listingsClinical drug / strength (SCD) hydrochloride 10 MGRxCUI 1738483hydrochloride 20 MGRxCUI 1738495hydrochloride 30 MGRxCUI 1738503hydrochloride 40 MGRxCUI 1738511mesylate 10 MGRxCUI 1738515mesylate 20 MGRxCUI 1738519mesylate 30 MGRxCUI 1738523mesylate 40 MGRxCUI 1738527
Look up RxCUI 32937 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Paroxetine supply and shortage status
Whether Paroxetine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Paroxetine supply by package: listed, ending or in shortage
80 packages of Paroxetine are on record for the current products; 78 are in the newest FDA directory snapshot and 2 are not. No package here appears in an active FDA shortage entry. Pharmacy prices are on record for 60, steady over the last four weeks.
| Package | Labeler | FDA directory | Marketing end | FDA shortage | Pharmacy price (4-week change) |
|---|---|---|---|---|---|
| 30 capsules 7.5 mg Capsule · NDC 00574-0279-30 |
Padagis US LLC | Listed | None filed | None on record |
$2.62 per capsule -0.4% |
| 30 capsules 7.5 mg Capsule · NDC 00574-0279-30 |
Padagis US LLC | Listed | None filed | None on record |
$2.62 per capsule -0.4% |
| 100 tablets 10 mg Tablet · NDC 13107-0154-01 |
Aurolife Pharma LLC | Listed | None filed | None on record | not in the survey |
| 100 tablets 10 mg Tablet · NDC 13107-0154-01 |
Aurolife Pharma LLC | Listed | None filed | None on record | not in the survey |
| 500 tablets 10 mg Tablet · NDC 13107-0154-05 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 500 tablets 10 mg Tablet · NDC 13107-0154-05 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 30 tablets 10 mg Tablet · NDC 13107-0154-30 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 30 tablets 10 mg Tablet · NDC 13107-0154-30 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 90 tablets 10 mg Tablet · NDC 13107-0154-90 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 90 tablets 10 mg Tablet · NDC 13107-0154-90 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 1000 tablets 10 mg Tablet · NDC 13107-0154-99 |
Aurolife Pharma LLC | Listed | None filed | None on record | not in the survey |
| 1000 tablets 10 mg Tablet · NDC 13107-0154-99 |
Aurolife Pharma LLC | Listed | None filed | None on record | not in the survey |
| 1 tablet 10 mg Tablet · NDC 00904-5676-61 |
Major Pharmaceuticals | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 1 tablet 10 mg Tablet · NDC 00904-5676-61 |
Major Pharmaceuticals | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 1000 tablets 10 mg Tablet · NDC 00378-7001-10 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 1000 tablets 10 mg Tablet · NDC 00378-7001-10 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 30 tablets 10 mg Tablet · NDC 00378-7001-93 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 30 tablets 10 mg Tablet · NDC 00378-7001-93 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 30 tablets 10 mg Tablet · NDC 00615-8359-39 |
NCS HealthCare of KY, LLC dba Vangard Labs | Listed | None filed | None on record | not in the survey |
| 30 tablets 10 mg Tablet · NDC 00615-8359-39 |
NCS HealthCare of KY, LLC dba Vangard Labs | Listed | None filed | None on record | not in the survey |
| 30 tablets 10 mg Tablet · NDC 16714-0181-01 |
NorthStar Rx LLC | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 30 tablets 10 mg Tablet · NDC 16714-0181-01 |
NorthStar Rx LLC | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 90 tablets 10 mg Tablet · NDC 16714-0181-02 |
NorthStar Rx LLC | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 90 tablets 10 mg Tablet · NDC 16714-0181-02 |
NorthStar Rx LLC | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 100 tablets 10 mg Tablet · NDC 16714-0181-03 |
NorthStar Rx LLC | Not in the snapshot | None filed | None on record |
$0.062 per tablet -0.4% |
| 100 tablets 10 mg Tablet · NDC 16714-0181-03 |
NorthStar Rx LLC | Not in the snapshot | None filed | None on record |
$0.062 per tablet -0.4% |
| 500 tablets 10 mg Tablet · NDC 16714-0181-04 |
NorthStar Rx LLC | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 500 tablets 10 mg Tablet · NDC 16714-0181-04 |
NorthStar Rx LLC | Listed | None filed | None on record |
$0.062 per tablet -0.4% |
| 100 tablets 20 mg Tablet · NDC 13107-0155-01 |
Aurolife Pharma LLC | Listed | None filed | None on record | not in the survey |
| 100 tablets 20 mg Tablet · NDC 13107-0155-01 |
Aurolife Pharma LLC | Listed | None filed | None on record | not in the survey |
| 500 tablets 20 mg Tablet · NDC 13107-0155-05 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.061 per tablet -3.2% |
| 500 tablets 20 mg Tablet · NDC 13107-0155-05 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.061 per tablet -3.2% |
| 30 tablets 20 mg Tablet · NDC 13107-0155-30 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.061 per tablet -3.2% |
| 30 tablets 20 mg Tablet · NDC 13107-0155-30 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.061 per tablet -3.2% |
| 90 tablets 20 mg Tablet · NDC 13107-0155-90 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.061 per tablet -3.2% |
| 90 tablets 20 mg Tablet · NDC 13107-0155-90 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.061 per tablet -3.2% |
| 1000 tablets 20 mg Tablet · NDC 13107-0155-99 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.061 per tablet -3.2% |
| 1000 tablets 20 mg Tablet · NDC 13107-0155-99 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.061 per tablet -3.2% |
| 1 tablet 20 mg Tablet · NDC 00904-5677-61 |
Major Pharmaceuticals | Listed | None filed | None on record |
$0.061 per tablet -3.2% |
| 1 tablet 20 mg Tablet · NDC 00904-5677-61 |
Major Pharmaceuticals | Listed | None filed | None on record |
$0.061 per tablet -3.2% |
| 1000 tablets 20 mg Tablet · NDC 00378-7002-10 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.061 per tablet -3.2% |
| 1000 tablets 20 mg Tablet · NDC 00378-7002-10 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.061 per tablet -3.2% |
| 30 tablets 20 mg Tablet · NDC 00378-7002-93 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.061 per tablet -3.2% |
| 30 tablets 20 mg Tablet · NDC 00378-7002-93 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.061 per tablet -3.2% |
| 15 tablets 20 mg Tablet · NDC 00615-7985-05 |
NCS HealthCare of KY, LLC dba Vangard Labs | Listed | None filed | None on record | not in the survey |
| 15 tablets 20 mg Tablet · NDC 00615-7985-05 |
NCS HealthCare of KY, LLC dba Vangard Labs | Listed | None filed | None on record | not in the survey |
| 30 tablets 20 mg Tablet · NDC 00615-7985-39 |
NCS HealthCare of KY, LLC dba Vangard Labs | Listed | None filed | None on record | not in the survey |
| 30 tablets 20 mg Tablet · NDC 00615-7985-39 |
NCS HealthCare of KY, LLC dba Vangard Labs | Listed | None filed | None on record | not in the survey |
| 100 tablets 30 mg Tablet · NDC 13107-0156-01 |
Aurolife Pharma LLC | Listed | None filed | None on record | not in the survey |
| 100 tablets 30 mg Tablet · NDC 13107-0156-01 |
Aurolife Pharma LLC | Listed | None filed | None on record | not in the survey |
| 500 tablets 30 mg Tablet · NDC 13107-0156-05 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.095 per tablet +1.6% |
| 500 tablets 30 mg Tablet · NDC 13107-0156-05 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.095 per tablet +1.6% |
| 30 tablets 30 mg Tablet · NDC 13107-0156-30 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.095 per tablet +1.6% |
| 30 tablets 30 mg Tablet · NDC 13107-0156-30 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.095 per tablet +1.6% |
| 90 tablets 30 mg Tablet · NDC 13107-0156-90 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.095 per tablet +1.6% |
| 90 tablets 30 mg Tablet · NDC 13107-0156-90 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.095 per tablet +1.6% |
| 1000 tablets 30 mg Tablet · NDC 13107-0156-99 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.095 per tablet +1.6% |
| 1000 tablets 30 mg Tablet · NDC 13107-0156-99 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.095 per tablet +1.6% |
| 1000 tablets 30 mg Tablet · NDC 00378-7003-10 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.095 per tablet +1.6% |
| 1000 tablets 30 mg Tablet · NDC 00378-7003-10 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.095 per tablet +1.6% |
| 30 tablets 30 mg Tablet · NDC 00378-7003-93 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.095 per tablet +1.6% |
| 30 tablets 30 mg Tablet · NDC 00378-7003-93 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.095 per tablet +1.6% |
| 30 tablets 30 mg Tablet · NDC 00615-8173-39 |
NCS HealthCare of KY, LLC dba Vangard Labs | Listed | None filed | None on record | not in the survey |
| 30 tablets 30 mg Tablet · NDC 00615-8173-39 |
NCS HealthCare of KY, LLC dba Vangard Labs | Listed | None filed | None on record | not in the survey |
| 100 tablets 40 mg Tablet · NDC 13107-0157-01 |
Aurolife Pharma LLC | Listed | None filed | None on record | not in the survey |
| 100 tablets 40 mg Tablet · NDC 13107-0157-01 |
Aurolife Pharma LLC | Listed | None filed | None on record | not in the survey |
| 500 tablets 40 mg Tablet · NDC 13107-0157-05 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.097 per tablet -1.8% |
| 500 tablets 40 mg Tablet · NDC 13107-0157-05 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.097 per tablet -1.8% |
| 30 tablets 40 mg Tablet · NDC 13107-0157-30 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.097 per tablet -1.8% |
| 30 tablets 40 mg Tablet · NDC 13107-0157-30 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.097 per tablet -1.8% |
| 90 tablets 40 mg Tablet · NDC 13107-0157-90 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.097 per tablet -1.8% |
| 90 tablets 40 mg Tablet · NDC 13107-0157-90 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.097 per tablet -1.8% |
| 1000 tablets 40 mg Tablet · NDC 13107-0157-99 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.097 per tablet -1.8% |
| 1000 tablets 40 mg Tablet · NDC 13107-0157-99 |
Aurolife Pharma LLC | Listed | None filed | None on record |
$0.097 per tablet -1.8% |
| 1000 tablets 40 mg Tablet · NDC 00378-7004-10 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.097 per tablet -1.8% |
| 1000 tablets 40 mg Tablet · NDC 00378-7004-10 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.097 per tablet -1.8% |
| 30 tablets 40 mg Tablet · NDC 00378-7004-93 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.097 per tablet -1.8% |
| 30 tablets 40 mg Tablet · NDC 00378-7004-93 |
Mylan Pharmaceuticals Inc. | Listed | None filed | None on record |
$0.097 per tablet -1.8% |
| 30 tablets 40 mg Tablet · NDC 00615-8174-39 |
NCS HealthCare of KY, LLC dba Vangard Labs | Listed | None filed | None on record | not in the survey |
| 30 tablets 40 mg Tablet · NDC 00615-8174-39 |
NCS HealthCare of KY, LLC dba Vangard Labs | Listed | None filed | None on record | not in the survey |
From our pharmacy team
If your usual package is unavailable
A missing package size or labeler is usually not a shortage of the medicine. Ask the pharmacy for the same strength and form from another labeler, or a different package size; both are routine for a generic. If the FDA lists a shortage for your presentation, ask what the pharmacy can order and when, and whether your prescriber would consider another strength or form. Never adjust the dose yourself to stretch a supply.
Ask Dr. Staiger about Paroxetine supply →Sources: the openFDA NDC directory (newest complete sync, Oct 1, 2026), the FDA Drug Shortages database as we last synced it, and CMS NADAC as of Sep 30, 2026. A package absent from the snapshot was not certified by its labeler this week; it may still be on shelves.
What pharmacies pay for Paroxetine, and how your price compares
The figures below are the national average invoice price retail pharmacies pay for the drug itself (CMS’s NADAC survey, as of Sep 30, 2026), package by package. They are not a retail price and not what you pay at the counter: a pharmacy adds a dispensing fee and margin, and an insurance copay is set by your plan. They do tell you whether Paroxetine is an inexpensive medicine, which strengths and packages cost pharmacies more, and how far your own price sits from the benchmark.
7.5 mg Capsule · Oral pharmacies pay about $2.62 per capsule
One priced package at $2.62 per capsule.
| Package | Labeler | Pharmacy pays | Per package | 4-week change | Medicaid paid per unit (Q1 2026, 12 mo) |
|---|---|---|---|---|---|
| 30 capsules NDC 00574-0279-30 |
Padagis US LLC | $2.62 per capsule | $78.67 30 capsules | -0.4% | $2.80 |
| 30 capsules NDC 00574-0279-30 |
Padagis US LLC | $2.62 per capsule | $78.67 30 capsules | -0.4% | $2.80 |
| 30 capsules NDC 43547-0409-03 |
Solco Healthcare LLC | $2.62 per capsule | $78.67 30 capsules | -0.4% | $2.87 |
| 30 capsules NDC 43547-0409-03 |
Solco Healthcare LLC | $2.62 per capsule | $78.67 30 capsules | -0.4% | $2.87 |
12.5 mg Extended-release tablet · Oral pharmacies pay about $0.520 per tablet
One priced package at $0.520 per tablet.
| Package | Labeler | Pharmacy pays | Per package | 4-week change | Medicaid paid per unit (Q1 2026, 12 mo) |
|---|---|---|---|---|---|
| 30 tablets NDC 60505-1316-03 |
Apotex Corp | $0.520 per tablet | $15.60 30 tablets | +5.8% | $0.761 |
| 30 tablets NDC 60505-1316-03 |
Apotex Corp | $0.520 per tablet | $15.60 30 tablets | +5.8% | $0.761 |
| 30 tablets NDC 62135-0425-30 |
Chartwell RX, LLC | $0.520 per tablet | $15.60 30 tablets | +5.8% | no Medicaid claims |
| 30 tablets NDC 62135-0425-30 |
Chartwell RX, LLC | $0.520 per tablet | $15.60 30 tablets | +5.8% | no Medicaid claims |
| 30 tablets NDC 62175-0470-32 |
Lannett Company, Inc. | $0.520 per tablet | $15.60 30 tablets | +5.8% | $0.736 |
| 30 tablets NDC 62175-0470-32 |
Lannett Company, Inc. | $0.520 per tablet | $15.60 30 tablets | +5.8% | $0.736 |
The 6 cheapest of 8 priced packages are shown.
25 mg Extended-release tablet · Oral pharmacies pay about $0.386 per tablet
Across 10 priced packages: $0.386 to $10.80 per tablet.
| Package | Labeler | Pharmacy pays | Per package | 4-week change | Medicaid paid per unit (Q1 2026, 12 mo) |
|---|---|---|---|---|---|
| 30 tablets NDC 60505-1317-03 |
Apotex Corp | $0.386 per tablet | $11.57 30 tablets | -5.0% | $0.697 |
| 30 tablets NDC 60505-1317-03 |
Apotex Corp | $0.386 per tablet | $11.57 30 tablets | -5.0% | $0.697 |
| 30 tablets NDC 62135-0426-30 |
Chartwell RX, LLC | $0.386 per tablet | $11.57 30 tablets | -5.0% | no Medicaid claims |
| 30 tablets NDC 62135-0426-30 |
Chartwell RX, LLC | $0.386 per tablet | $11.57 30 tablets | -5.0% | no Medicaid claims |
| 30 tablets NDC 62175-0471-32 |
Lannett Company, Inc. | $0.386 per tablet | $11.57 30 tablets | -5.0% | $0.695 |
| 30 tablets NDC 62175-0471-32 |
Lannett Company, Inc. | $0.386 per tablet | $11.57 30 tablets | -5.0% | $0.695 |
The 6 cheapest of 10 priced packages are shown.
37.5 mg Extended-release tablet · Oral pharmacies pay about $0.397 per tablet
One priced package at $0.397 per tablet.
| Package | Labeler | Pharmacy pays | Per package | 4-week change | Medicaid paid per unit (Q1 2026, 12 mo) |
|---|---|---|---|---|---|
| 30 tablets NDC 60505-1318-03 |
Apotex Corp | $0.397 per tablet | $11.92 30 tablets | -0.6% | $0.774 |
| 30 tablets NDC 60505-1318-03 |
Apotex Corp | $0.397 per tablet | $11.92 30 tablets | -0.6% | $0.774 |
| 30 tablets NDC 62135-0427-30 |
Chartwell RX, LLC | $0.397 per tablet | $11.92 30 tablets | -0.6% | no Medicaid claims |
| 30 tablets NDC 62135-0427-30 |
Chartwell RX, LLC | $0.397 per tablet | $11.92 30 tablets | -0.6% | no Medicaid claims |
| 30 tablets NDC 62175-0472-32 |
Lannett Company, Inc. | $0.397 per tablet | $11.92 30 tablets | -0.6% | $0.750 |
| 30 tablets NDC 62175-0472-32 |
Lannett Company, Inc. | $0.397 per tablet | $11.92 30 tablets | -0.6% | $0.750 |
The 6 cheapest of 8 priced packages are shown.
10 mg Tablet · Oral pharmacies pay about $0.062 per tablet
One priced package at $0.062 per tablet.
| Package | Labeler | Pharmacy pays | Per package | 4-week change | Medicaid paid per unit (Q1 2026, 12 mo) |
|---|---|---|---|---|---|
| 1000 tablets NDC 00378-7001-10 |
Mylan Pharmaceuticals Inc. | $0.062 per tablet | $61.89 1000 tablets | -0.4% | $0.294 |
| 1000 tablets NDC 00378-7001-10 |
Mylan Pharmaceuticals Inc. | $0.062 per tablet | $61.89 1000 tablets | -0.4% | $0.294 |
| 30 tablets NDC 00378-7001-93 |
Mylan Pharmaceuticals Inc. | $0.062 per tablet | $1.86 30 tablets | -0.4% | $0.342 |
| 30 tablets NDC 00378-7001-93 |
Mylan Pharmaceuticals Inc. | $0.062 per tablet | $1.86 30 tablets | -0.4% | $0.342 |
| 1 tablet NDC 00904-5676-61 |
Major Pharmaceuticals | $0.062 per tablet | $6.19 100 tablet | -0.4% | $0.408 |
| 1 tablet NDC 00904-5676-61 |
Major Pharmaceuticals | $0.062 per tablet | $6.19 100 tablet | -0.4% | $0.408 |
The 6 cheapest of 44 priced packages are shown.
20 mg Tablet · Oral pharmacies pay about $0.061 per tablet
Across 40 priced packages: $0.061 to $10.74 per tablet.
| Package | Labeler | Pharmacy pays | Per package | 4-week change | Medicaid paid per unit (Q1 2026, 12 mo) |
|---|---|---|---|---|---|
| 1000 tablets NDC 00378-7002-10 |
Mylan Pharmaceuticals Inc. | $0.061 per tablet | $61.08 1000 tablets | -3.2% | $1.29 |
| 1000 tablets NDC 00378-7002-10 |
Mylan Pharmaceuticals Inc. | $0.061 per tablet | $61.08 1000 tablets | -3.2% | $1.29 |
| 30 tablets NDC 00378-7002-93 |
Mylan Pharmaceuticals Inc. | $0.061 per tablet | $1.83 30 tablets | -3.2% | $0.543 |
| 30 tablets NDC 00378-7002-93 |
Mylan Pharmaceuticals Inc. | $0.061 per tablet | $1.83 30 tablets | -3.2% | $0.543 |
| 1 tablet NDC 00904-5677-61 |
Major Pharmaceuticals | $0.061 per tablet | $6.11 100 tablet | -3.2% | $0.514 |
| 1 tablet NDC 00904-5677-61 |
Major Pharmaceuticals | $0.061 per tablet | $6.11 100 tablet | -3.2% | $0.514 |
The 6 cheapest of 40 priced packages are shown.
30 mg Tablet · Oral pharmacies pay about $0.095 per tablet
Across 34 priced packages: $0.095 to $10.81 per tablet.
| Package | Labeler | Pharmacy pays | Per package | 4-week change | Medicaid paid per unit (Q1 2026, 12 mo) |
|---|---|---|---|---|---|
| 1000 tablets NDC 00378-7003-10 |
Mylan Pharmaceuticals Inc. | $0.095 per tablet | $95.43 1000 tablets | +1.6% | $0.328 |
| 1000 tablets NDC 00378-7003-10 |
Mylan Pharmaceuticals Inc. | $0.095 per tablet | $95.43 1000 tablets | +1.6% | $0.328 |
| 30 tablets NDC 00378-7003-93 |
Mylan Pharmaceuticals Inc. | $0.095 per tablet | $2.86 30 tablets | +1.6% | $0.356 |
| 30 tablets NDC 00378-7003-93 |
Mylan Pharmaceuticals Inc. | $0.095 per tablet | $2.86 30 tablets | +1.6% | $0.356 |
| 500 tablets NDC 13107-0156-05 |
Aurolife Pharma LLC | $0.095 per tablet | $47.72 500 tablets | +1.6% | no Medicaid claims |
| 500 tablets NDC 13107-0156-05 |
Aurolife Pharma LLC | $0.095 per tablet | $47.72 500 tablets | +1.6% | no Medicaid claims |
The 6 cheapest of 34 priced packages are shown.
40 mg Tablet · Oral pharmacies pay about $0.097 per tablet
Across 38 priced packages: $0.097 to $11.50 per tablet.
| Package | Labeler | Pharmacy pays | Per package | 4-week change | Medicaid paid per unit (Q1 2026, 12 mo) |
|---|---|---|---|---|---|
| 1000 tablets NDC 00378-7004-10 |
Mylan Pharmaceuticals Inc. | $0.097 per tablet | $96.55 1000 tablets | -1.8% | $0.338 |
| 1000 tablets NDC 00378-7004-10 |
Mylan Pharmaceuticals Inc. | $0.097 per tablet | $96.55 1000 tablets | -1.8% | $0.338 |
| 30 tablets NDC 00378-7004-93 |
Mylan Pharmaceuticals Inc. | $0.097 per tablet | $2.90 30 tablets | -1.8% | $0.652 |
| 30 tablets NDC 00378-7004-93 |
Mylan Pharmaceuticals Inc. | $0.097 per tablet | $2.90 30 tablets | -1.8% | $0.652 |
| 500 tablets NDC 13107-0157-05 |
Aurolife Pharma LLC | $0.097 per tablet | $48.28 500 tablets | -1.8% | no Medicaid claims |
| 500 tablets NDC 13107-0157-05 |
Aurolife Pharma LLC | $0.097 per tablet | $48.28 500 tablets | -1.8% | no Medicaid claims |
The 6 cheapest of 38 priced packages are shown.
How does your price compare?
Pick the strength, enter how many units you received and what you paid. The comparison runs in your browser; nothing you type is sent anywhere.
An insurance copay is set by your plan and can be higher or lower than the drug’s cost; it is not a pharmacy price.
What to ask at the counter
- What is your cash price for this exact strength and quantity, and is it lower than my copay?
- Does a discount program or a 90-day supply change the per-dose price?
- Is a different package size or another labeler of the same generic cheaper today?
Sources: CMS National Average Drug Acquisition Cost (NADAC), the weekly survey of retail pharmacy invoice prices; packages are shown when priced within the survey’s last 180 days. Medicaid figures are CMS State Drug Utilization Data, gross payment per unit over the trailing twelve months, dispensing fees included and rebates not subtracted. Neither is a patient price.
Paroxetine brand names
Paroxetine is sold under 4 brand names in the FDA directory — Brisdelle, Paxil, Paxil Cr, Pexeva. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Paroxetine: manufacturers and labelers
43 companies list Paroxetine products with the FDA. By number of product records, the largest are Apotex Corp, Remedyrepack Inc., Aphena Pharma Solutions - Tennessee, LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
…and 19 more on the FDA NDC directory.
Paroxetine drug class (RxNorm)
Paroxetine belongs to the Serotonin Reuptake Inhibitor class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Paroxetine page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Padagis US LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →